David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
16 jaar Canadian Hemophilia Prophylaxis Study: primaire profylaxe ‘op maat’
jun 2018 | Benigne hematologie